Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings

Licensing Agreement:
Genmab has exercised its option to license a second anti-glycan monoclonal antibody from Scancell Holdings plc, following an exclusive evaluation period announced in June 202412.

Commercial Rights:
Genmab has been granted worldwide exclusive rights for the development and commercialisation of novel therapeutic products using the Scancell antibody12.

Financial Terms:
Scancell will receive an upfront payment and potential development, regulatory, and commercial milestone payments of up to $630 million if Genmab develops and commercialises products across all defined modalities. Additionally, Scancell will receive low single-digit royalties on net sales of commercialised products12.

GlyMab Platform:
The licensed antibody is developed using Scancell's proprietary GlyMab platform, which targets sugar motifs associated with tumour malignancies12.

Existing Relationship:
This is the second commercial license agreement between Scancell and Genmab, following an earlier agreement signed in October 202212.

Sources:

1. https://www.investegate.co.uk/announcement/rns/scancell-holdings--sclp/second-commercial-license-agreement-with-genmab-/8588688

2. https://calculuscapital.com/scancell-achieve-second-licensing-agreement/